# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001104659-26-005368
**Filing Date:** 2026-1
**Character Count:** 12090
**Document Hash:** 9336737c1da8f911610c9ff51ebb002a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-005368.hdr.sgml**: 20260121

**ACCESSION NUMBER**: 0001104659-26-005368

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260121

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260121

**DATE AS OF CHANGE**: 20260121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37467
- **FILM NUMBER:** 26547935

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 21, 2026**

------

**Astria Therapeutics, Inc.**

**(Exact Name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37467** | **26-3687168** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **22 Boston Wharf Road**<br> **10th Floor** |  |
| **Boston** **, Massachusetts** | **02210** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

Registrant's telephone number, including area code: **(617) 349-1971**

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading <br> Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.001 per share** | **ATXS** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

A special meeting of stockholders of Astria Therapeutics, Inc., a Delaware corporation (the "**Company**"), was held on January 21, 2026 at 9:00 a.m., Eastern Time at 22 Boston Wharf Road, 10th Floor, Boston, Massachusetts 02210 (the "**Special Meeting**"). As of the close of business on December 9, 2025, the record date for the Special Meeting (the "**Record Date**"), 57,084,838 shares of the Company's common stock, par value $0.001 per share ("**Astria Common Stock**"), were outstanding and entitled to vote at the Special Meeting. Each record holder of Astria Common Stock was entitled to one vote for each share of Astria Common Stock owned as of the Record Date.

At the Special Meeting, a total of 35,757,073 shares of Astria Common Stock were present in person or represented by proxy, representing approximately 62.64% of the voting power of the shares of Astria Common Stock issued and outstanding and entitled to vote at the Special Meeting, and, therefore, a quorum was present for the Special Meeting. A summary of the voting results for the proposals presented at the Special Meeting, each of which is described in detail in the Company's definitive proxy statement, dated December 18, 2025, and first mailed to the Company's stockholders on or about the date thereof (the "**Proxy Statement**"), is set forth below.

***Merger Proposal***

As previously announced, on October 14, 2025, the Company entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "**Merger Agreement**") with BioCryst Pharmaceuticals, Inc., a Delaware corporation ("**BioCryst**"), and Axel Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of BioCryst. Adoption of the Merger Agreement (the "**Merger Proposal**") required the affirmative vote of holders of not less than a majority of the outstanding shares of Astria Common Stock.

At the Special Meeting, the Company's stockholders voted upon and approved the Merger Proposal. The votes on this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstaining** | **Broker Non-Votes** |
| 35673135 | 12977 | 70961 |  |

---

 **

***Compensation Proposal***

 **

At the Special Meeting, the Company's stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Parachute Compensation" and its accompanying footnotes which is included in the section of the Proxy Statement entitled "*The Merger—Interests of Astria's Directors and Executive Officers in the Merger*," as required by Section 14A of the Securities Exchange Act of 1934, as amended, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "**Compensation Proposal**"). Approval of this proposal required the affirmative vote of holders of shares of Astria Common Stock having a majority in voting power of the votes cast by the holders of all of the shares of Astria Common Stock present or represented at the Special Meeting and voting affirmatively or negatively on such matter. The votes on this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstaining<sup>(1)</sup>** | **Broker Non-Votes** |
| 33236762 | 2035104 | 485206 |  |

---

 ****

&nbsp;&nbsp;&nbsp;&nbsp;(1) Abstentions were not considered votes cast affirmatively or negatively and had no effect on the outcome
of the vote on the Compensation Proposal.

 **

***Adjournment Proposal***

 **

Because the Merger Proposal was approved, the proposal to approve one or more adjournments of the Special Meeting to a later date or dates, if there were insufficient votes to adopt the Merger Agreement on the date of the Special Meeting, was rendered moot and was not called for a vote at the Special Meeting.

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events.** |

---

On January 21, 2026, Astria issued a press release announcing the approval of the Merger Proposal.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [99.1](tm263644d1_ex99-1.htm) | [Press Release, dated January 21, 2026](tm263644d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASTRIA THERAPEUTICS, INC.** | **ASTRIA THERAPEUTICS, INC.** |
| Date: January 21, 2026 | By: | /s/ Ben Harshbarger |
|  |  | Ben Harshbarger |
|  |  | Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**ASTRIA STOCKHOLDERS VOTE TO** 

**APPROVE ACQUISITION BY BIOCRYST** 

**BOSTON, M.A., January 21, 2026**—Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger").

The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.

**About Astria Therapeutics** 

Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Astria's second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis.

**Cautionary Note Regarding Forward-Looking Statements** 

Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words and phrases such as "may," "approximately," "continue," "should," "expects," "projects," "anticipates," "is likely," "look ahead," "look forward," "believes," "will," "intends," "estimates," "strategy," "plan," "could," "potential," "possible" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include statements regarding, among other things, the anticipated timing of the closing of the Merger. Astria cautions readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the merger agreement with respect to the Merger; the outcome of any legal proceedings that may be instituted against BioCryst or Astria and the failure to satisfy any of the conditions to the Merger on a timely basis or at all. Additional factors that could cause results to differ materially from those described above can be found in BioCryst's Annual Report on Form 10-K for the year ended December 31, 2024, BioCryst's Quarterly Report on Form 10-Q for the three months ended September 30, 2025, Astria's Annual Report on Form 10-K for the year ended December 31, 2024, Astria's Quarterly Report on Form 10-Q for the three months ended September 30, 2025, and in other documents BioCryst and Astria file with the SEC, which are available on the SEC's website at *www.sec.gov*.

**Investor Relations and Media:** 

Elizabeth Higgins

<u>investors@astriatx.com</u>